Cover image for Quarterly Drug Pipeline: July 2025 Clinical insights and competitive intelligence on anticipated drugs in development Prime Therapeutics /quarterly-drug-pipeline-july-2025 Prime...

Managed Healthcare Executive: A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member,...

Urick, senior principal health outcomes researcher, shares more about his Spotlight Session at the Academy of Managed Care Pharmacy (AMCP)’s Annual Meeting

In this second of a two-part episode of the Pharmacy Friends podcast, industry experts discuss clinical evidence, drug information and appropriate patient selection for GLP-1 use

Event on Sept. 11 in Washington D.C. will feature the latest information on using GLP-1s to tackle the obesity epidemic.

What to expect at Academy of Managed Care Pharmacy (AMCP) Nexus 2023

Live updates from AMCP Annual Meeting

Pat Gleason, assistant vice president, health outcomes, and David Eckwright, senior director, clinical project and program management, share an overview of Prime’s data and insights slated for this...

publications Quarterly Drug Pipeline: October 2024 Clinical insights and competitive intelligence on anticipated drugs in development October 31, 2024 Editor-in-chief's message Welcome to the Prime...

Prime to present seven studies and receive the 2024 JMCP Award for Excellence

GLP-1 year two cost effectiveness study abstract

The event emphasizes additional measures for obesity therapy.

publications Quarterly Drug Pipeline: October 2025 Clinical insights and competitive intelligence on anticipated drugs in development October 30, 2025 Editor-in-chief's message Welcome to the Prime...

Forbes

Prime Therapeutics researchers share more about award-winning real-world research

Pharmacy Practice News, originally published by Specialty Pharmacy Continuum

BioSpace: As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health outcomes—evidenced by successful studies in therapeutic areas like...

As demand for GLP-1a drugs for weight loss has increased, new data provides additional insights about this new class of medications.

publications Quarterly Drug Pipeline: July 2024 Clinical insights and competitive intelligence on anticipated drugs in development Editor-in-chief's message Welcome to the Prime Quarterly Drug...

Quarterly Drug Pipeline: April 2024 Clinical insights and competitive intelligence on anticipated drugs in development Drug Pipeline Clinical insights and competitive intelligence on anticipated...